Nonprofit
Multidisciplinary Association for Psychedelic Studies (MAPS)
About Us
Founded in 1986, the Multidisciplinary Association for Psychedelic Studies (MAPS) is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana.
MAPS is currently sponsoring large-scale, FDA-regulated Phase 3 clinical trials of MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD), which was designated a Breakthrough Therapy by the FDA in 2017. These studies are the final stage of research required before MAPS can submit a New Drug Application to the FDA for approval, anticipated in 2021.
Founded in 1986, the Multidisciplinary Association for Psychedelic Studies (MAPS) is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana.
MAPS is currently sponsoring large-scale, FDA-regulated Phase 3 clinical trials of MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD), which was designated a Breakthrough Therapy by the FDA in 2017. These studies are the final stage of research required before MAPS can submit a New Drug Application to the FDA for approval, anticipated in 2021.
Issue Areas Include
- Education
- Health & Medicine
- Mental Health
- Research & Social Science
- Science & Technology
Location
- 1115 Mission Street, Santa Cruz, CA 95060, United States
